Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Le Gars

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
The Journal of Infectious Diseases|September 23, 2016
Increased Proinflammatory Responses of Monocytes and Plasmacytoid Dendritic Cells to Influenza A Virus Infection During PregnancyMathieu Le Gars, Alexander W Kay, Nicholas L Bayless, et al.
The Journal of Infectious Diseases|April 16, 2022
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 VaccineMathieu Le Gars, Jerald Sadoff, Frank Struyf, et al.
Eclinicalmedicine|January 27, 2025
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialGabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, et al.
Human Vaccines & Immunotherapeutics|January 27, 2025
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trialJelena Tica, Veronica V Rezelj, Benoit Baron, et al.
Genes and Immunity|September 24, 2025
The epigenomic landscape of bronchial epithelial cells reveals the establishment of trained immunityJeanne Bigot, Rachel Legendre, Juliette Hamroune, et al.
Clinical Pharmacology and Therapeutics|November 15, 2022
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation ApproachAnna Dari, Muriel Boulton, Martine Neyens, et al.
Journal of the Pediatric Infectious Diseases Society|September 28, 2024
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of AgeJavier Ruiz-Guiñazú, Mathieu Le Gars, Vicky Cárdenas, et al.
Vaccine|May 5, 2024
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding studyVicky Cárdenas, Mathieu Le Gars, Carla Truyers, et al.
Vaccine|June 25, 2024
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialMathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, et al.
Human Vaccines & Immunotherapeutics|August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancyGloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Journal of Infectious Diseases|September 23, 2016
Increased Proinflammatory Responses of Monocytes and Plasmacytoid Dendritic Cells to Influenza A Virus Infection During PregnancyMathieu Le Gars, Alexander W Kay, Nicholas L Bayless, et al.
The Journal of Infectious Diseases|April 16, 2022
Impact of Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 VaccineMathieu Le Gars, Jerald Sadoff, Frank Struyf, et al.
Eclinicalmedicine|January 27, 2025
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialGabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, et al.
Human Vaccines & Immunotherapeutics|January 27, 2025
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trialJelena Tica, Veronica V Rezelj, Benoit Baron, et al.
Genes and Immunity|September 24, 2025
The epigenomic landscape of bronchial epithelial cells reveals the establishment of trained immunityJeanne Bigot, Rachel Legendre, Juliette Hamroune, et al.
Clinical Pharmacology and Therapeutics|November 15, 2022
Quantifying Antibody Persistence After a Single Dose of COVID-19 Vaccine Ad26.COV2.S in Humans Using a Mechanistic Modeling and Simulation ApproachAnna Dari, Muriel Boulton, Martine Neyens, et al.
Journal of the Pediatric Infectious Diseases Society|September 28, 2024
Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16-17 Years of AgeJavier Ruiz-Guiñazú, Mathieu Le Gars, Vicky Cárdenas, et al.
Vaccine|May 5, 2024
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding studyVicky Cárdenas, Mathieu Le Gars, Carla Truyers, et al.
Vaccine|June 25, 2024
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialMathieu Le Gars, Jerald Sadoff, Vicky Cárdenas, et al.
Human Vaccines & Immunotherapeutics|August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancyGloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
Pageof 5